Print  |  Close

A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer


Active: Yes
Cancer Type: Neuroendocrine Tumor
Prostate Cancer
Unknown Primary
NCT ID: NCT04702737
Trial Phases: Phase I Protocol IDs: 20200040 (primary)
NCI-2021-08862
Eligibility: 18 Years and older, Male Study Type: Treatment
Study Sponsor: Amgen, Inc.
NCI Full Details: http://clinicaltrials.gov/show/NCT04702737

Summary

To evaluate the safety and tolerability of Tarlatamab and will determine the maximum
tolerated dose (MTD) or recommended phase 2 dose (RP2D).
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.